Journal
NEUROSCIENCE RESEARCH
Volume 122, Issue -, Pages 45-50Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.neures.2017.04.003
Keywords
Parkinson's disease; Levodopa-induced dyskinesia; Zonisamide; Adenosine; Endocannabinoid
Categories
Funding
- Sumitomo Dainippon Pharma Co. Ltd.
- Kansai Medical University
Ask authors/readers for more resources
To investigate the difference in results according to the mode of levodopa administration and the effect of zonisamide (ZNS), we analyzed the mRNA expression of dopaminergic and non-dopaminergic receptors in the striatum of Parkinson model rats in relation to the development of levodopa-induced dyskinesia (LID). Unilateral Parkinson model rats were subdivided into 4 groups and treated as follows: no medication (group N), continuous levodopa infusion (group C), intermittent levodopa injection (group I), and intermittent levodopa and ZNS injection (group Z). Two weeks after the treatment, LID was observed in group I and Z, but less severe in group Z. The level of both D1 and D2 receptor mRNAs was elevated in groups I and Z, but only D2 receptor mRNA expression was elevated in group C. Adenosine A2A receptor mRNA showed increased expression only in group I. The level of endocannabinoid CB1 receptor mRNA was elevated in groups N, C, and I, but not in group Z. Intermittent injection of levodopa caused LID, in association with elevated expression of D1 and A2A receptors. ZNS ameliorated the development of LID and inhibited up-regulation of A2A and CB1 receptors. Modulation of these receptors may lead to therapeutic approaches for dyskinesia. (C) 2017 Elsevier Ireland Ltd and Japan Neuroscience Society. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available